Identifying clinical and proteomic markers for early diagnosis and prognosis prediction of major psychiatric disorders.

Autor: Lee H; Department of Neuropsychiatry, Seoul National University Hospital, Seoul, Republic of Korea., Han D; Proteomics Core Facility, Biomedical Research Institute, Seoul National University Hospital, Seoul, Republic of Korea; Transdisciplinary Department of Medicine & Advanced Technology, Seoul National University Hospital, Seoul, Republic of Korea., Rhee SJ; Department of Neuropsychiatry, Seoul National University Hospital, Seoul, Republic of Korea., Lee J; Department of Psychiatry, Seoul St. Mary's Hospital, Seoul, Republic of Korea., Kim J; Medical Research Collaborating Center, Seoul National University Hospital, Seoul, Republic of Korea., Lee Y; Department of Neuropsychiatry, Kosin University Gospel Hospital, Busan, Republic of Korea., Kim EY; Mental Health Center, Seoul National University Health Care Center, Seoul, Republic of Korea; Department of Human Systems Medicine, Seoul National University College of Medicine, Seoul, Republic of Korea., Park DY; Department of Psychiatry, National Center for Mental Health, Seoul, Republic of Korea., Roh S; Department of Neuropsychiatry, Hanyang University Hospital, Seoul, Republic of Korea., Baik M; Department of Psychiatry, Kyung Hee University Medical Center, Kyung Hee University School of Medicine, Seoul, Republic of Korea., Jung HY; Department of Psychiatry, SMG-SNU Boramae Medical Center, Seoul, Republic of Korea; Department of Psychiatry, Seoul National University College of Medicine, Seoul, Republic of Korea., Lee TY; Department of Psychiatry, Kyungpook National University Hospital, Daegu, Republic of Korea; Department of Psychiatry, Kyungpook National University School of Medicine, Daegu, Republic of Korea., Kim M; Department of Neuropsychiatry, Seoul National University Hospital, Seoul, Republic of Korea., Kim H; Proteomics Core Facility, Biomedical Research Institute, Seoul National University Hospital, Seoul, Republic of Korea., Kim SH; Department of Neuropsychiatry, Seoul National University Hospital, Seoul, Republic of Korea., Kwon JS; Department of Neuropsychiatry, Seoul National University Hospital, Seoul, Republic of Korea; Department of Psychiatry, Seoul National University College of Medicine, Seoul, Republic of Korea; Institute of Human Behavioral Medicine, Seoul National University Medical Research Center, Seoul, Republic of Korea., Ahn YM; Department of Neuropsychiatry, Seoul National University Hospital, Seoul, Republic of Korea; Department of Psychiatry, Seoul National University College of Medicine, Seoul, Republic of Korea; Institute of Human Behavioral Medicine, Seoul National University Medical Research Center, Seoul, Republic of Korea. Electronic address: aym@snu.ac.kr., Ha K; Department of Psychiatry, University of British Columbia, Vancouver, British Columbia, Canada; Department of Psychiatry, Lions Gate Hospital - Vancouver Coastal Health, British Columbia, Canada. Electronic address: kyooseob.ha@ubc.ca.
Jazyk: angličtina
Zdroj: Journal of affective disorders [J Affect Disord] 2025 Jan 15; Vol. 369, pp. 886-896. Date of Electronic Publication: 2024 Oct 18.
DOI: 10.1016/j.jad.2024.10.054
Abstrakt: Background: To clarify if blood proteins can predict disease progression among individuals at clinical high-risk of severe mental illness (CHR-SMI), we developed a statistical model incorporating clinical and blood protein markers to distinguish the transition group (who developed severe mental illness) (CHR-SMI-T) and from non-transition group (CHR-SMI-NT) at baseline.
Methods: Ninety individuals (74 at CHR-SMI: 16 patients) were monitored for ≤4 years and were the focus of predictive models. Three predictive models (1 [100 clinical variables], 2 [158 peptides], and 3 [100 clinical variables +158 peptides]) were evaluated using area under the receiver operating characteristic (AUROC) values. Clinical and protein feature patterns were evaluated by linear mixed-effect analysis within the model at 12 and 24 months among patients who did (CHR-SMI-T) and did not transition (CHR-SMI-NT) and the entire group.
Result: Eighteen CHR-SMI individuals with major psychiatric disorders (first episode psychosis: 2; bipolar II disorder: 13; major depressive disorder; 3) developed disorders over an average of 17.7 months. The combined model showed the highest discriminatory performance (AUROC = 0.73). Cytosolic malate dehydrogenase and transgelin-2 levels were lower in the CHR-SMI-T than the CHR-SMI-NT group. Complement component C9, inter-alpha-trypsin inhibitor heavy chain H4, von Willebrand factor, and C-reactive protein were lower in the patient than the CHR-SMI-NT group. These differences were non-significant after FDR adjustment.
Limitations: Small sample, no control for medication use.
Conclusion: This exploratory study identified clinical and proteomic markers that might predict severe mental illness early onset, which could aid in early detection and intervention. Future studies with larger samples and controlled variables are needed to validate these findings.
Competing Interests: Declaration of competing interest YMA receives research support from or serves as a speaker for Janssesn Korea Ltd., Lundbeck Korea Co. Ltd., and Korea Otsuka Pharmaceutical. The remaining authors declare no competing interests.
(Copyright © 2024 Elsevier B.V. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: